Effect of novel limited-spectrum MMP inhibitor XL784 in abdominal aortic aneurysms

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 4, 2012, Pages 417-426

  Ennis, Terri ^a   Jin, Jianping ^a   Bartlett, Sarah ^a   Arif, Batool ^a   Grapperhaus, Kathy ^a   Curci, John A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aortic aneurysm; cardiovascular disease; metalloproteinase

Indexed keywords

CARDIOVASCULAR AGENT; DOXYCYCLINE; ELASTASE; ENZYME INHIBITOR; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG; XL 784;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASODILATATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; DILATATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELASTIN; HALF-LIFE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, INBRED C57BL; PANCREATIC ELASTASE; RANDOM ALLOCATION; SEVERITY OF ILLNESS INDEX;

EID: 84868534124     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248412455695     Document Type: Article

References (40)

1. Williams JM, Zhang J, North P, et al. Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am J Physiol Renal Physiol. 2011 ; 300 (4). F983 - F998
2. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001 ; 93 (3). 178-193
3. Drummond AH, Beckett P, Brown PD, et al. Preclinical and clinical studies of mmp inhibitors in cancer. Ann N Y Acad Sci. 1999 ; 878: 228-235
4. Bergoeing MP, Arif B, Hackmann AE, Ennis TL, Thompson RW, Curci JA. Cigarette smoking increases aortic dilatation without affecting matrix metalloproteinase-9 and -12 expression in a modified mouse model of aneurysm formation. J Vasc Surg. 2007 ; 45 (6). 1217-1227
5. Prall AK, Longo GM, Mayhan WG, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg. 2002 ; 35 (5). 923-929
6. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000 ; 105 (11). 1641-1649
7. Parodi FE, Mao D, Ennis TL, Pagano MB, Thompson RW. Oral administration of diferuloylmethane (curcumin) suppresses proinflammatory cytokines and destructive connective tissue remodeling in experimental abdominal aortic aneurysms. Ann Vasc Surg. 2006 ; 20 (3). 360-368
8. Dobrin PB, Mrkvicka R. Failure of elastin or collagen as possible critical connective tissue alterations underlying aneurysmal dilatation. Cardiovasc Surg. 1994 ; 2 (4). 484-488
9. Dobrin PB, Baker WH, Gley WC. Elastolytic and collagenolytic studies of arteries: Implications for the mechanical properties of aneurysms. Arch Surg. 1984 ; 119 (4). 405-409
10. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002 ; 110 (5). 625-632
11. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004 ; 24 (3). 429-434
12. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin ii-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003 ; 23 (3). 483-488
13. Thompson RW, Holmes DR, Mertens RA, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest. 1995 ; 96 (1). 318-326
14. Vine N, Powell J. Metalloproteinases in degenerative aortic disease. Clin Sci (Lond). 1991 ; 81 (2). 233-239
15. Davis V, Persidskaia R, Baca-Regen L, et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 1998 ; 18 (10). 1625-1633
16. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995 ; 15 (8). 1145-1151
17. Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thompson RW. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol. 2000 ; 11 (10). 1345-1352
18. Watanabe T, Sato A, Sawai T, et al. The elevated level of circulating matrix metalloproteinase-9 in patients with abdominal aortic aneurysms decreased to levels equal to those of healthy controls after an aortic repair. Ann Vasc Surg. 2006 ; 20 (3). 317-321
19. Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G, Franklin DP, Youkey JR.. The matrix metalloproteinase inhibitor bb-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg. 1999 ; 29 (1). 130-138
20. Karwowski JK, Markezich A, Whitson J, Abbruzzese TA, Zarins CK, Dalman RL. Dose-dependent limitation of arterial enlargement by the matrix metalloproteinase inhibitor rs-113,456. J Surg Res. 1999 ; 87 (1). 122-129
21. Moore G, Liao S, Curci JA, et al. Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). J Vasc Surg. 1999 ; 29 (3). 522-532
22. Treharne GD, Boyle JR, Goodall S, Loftus IM, Bell PR, Thompson MM. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br J Surg. 1999 ; 86 (8). 1053-1058
23. Castro MM, Kandasamy AD, Youssef N, Schulz R. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res. 2011 ; 64 (6). 551-560
24. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res. 1987 ; 66 (8). 1310-1314
25. Curci JA, Petrinec D, Liao SX, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg. 1998 ; 28 (6). 1082-1093
26. Bartoli M, Parodi F, Chu J, et al. Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann Vasc Surg. 2006 ; 20 (2). 228-236
27. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996 ; 23 (2). 336-346
28. Chung AW, Yang HH, Radomski MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res. 2008 ; 102 (8). e73 - e85
29. Curci JA, Mao D, Bohner DG, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg. 2000 ; 31 (2). 325-342
30. Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg. 2001 ; 34 (4). 606-610
31. Hackmann AE, Rubin BG, Sanchez LA, Geraghty PA, Thompson RW, Curci JA. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg. 2008 ; 48 (3). 519-526
32. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg. 2002 ; 36 (1). 1-12
33. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf. 2011 ; 34 (10). 821-837
34. Passier A, Smits-van Herwaarden A, van Puijenbroek E. Photo-onycholysis associated with the use of doxycycline. BMJ. 2004 ; 329 (7460). 265
35. Howard PA, Ellerbeck EF, Engelman KK, Patterson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2002 ; 11 (7). 569-576
36. Kovács Z, Kékesi KA, Baracskay P, Juhász G, Czurkó A. Doxycycline could aggravate the absence-like epileptic seizures of WAG/Rij rats via matrix metalloproteinase inhibition. Neurochem Int. 2011 ; 59 (5). 563-566
37. Therriault BL, Wilson JW, Barreto JN, Estes LL. Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. Mayo Clin Proc. 2010 ; 85 (8). 711-718
38. Ayaslioglu E, Erkek E, Oba AA, Cebecioglu E. Doxycycline-induced staining of permanent adult dentition. Aust Dent J. 2005 ; 50 (4). 273-275
39. Nelson R, Parker SRS. Doxycycline-induced staining of adult teeth: the first reported case. Arch Dermatol. 2006 ; 142 (8). 1081-1082
40. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res. 2006 ; 69 (3). 677-687